INSIDER
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

Robinhood Chain…
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources
SEC FORM 45m ago
HOUSE PTR5m ago
SEC 13F5m ago
ROBINHOOD CHAIN4m ago
SS
Corporate insider

Sloan Sheldon

Chief Medical OfficerCIK 0002038798

EDGAR filingsOpen in network
Disclosed transactions10
Buys / sells0 / 7
Max Insider Score28
Connections with evidence1

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
7
SS
Sloan SheldonChief Medical Officer
SYRESpyre Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
78.3K sh
May 1, 2026May 1, 2026
traded May 1, 2026
+0dSEC FORM 4

Evidence

Verified connections

  • Insider ofevidence
    Spyre Therapeutics, Inc.Chief Medical Officer · Jan 13, 2026
28
SS
Sloan SheldonChief Medical Officer
SYRESpyre Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL
$377K
5,059 sh
May 1, 2026
May 1, 2026
traded May 1, 2026
+0d
SEC FORM 4

Evidence

8
SS
Sloan SheldonChief Medical Officer
SYRESpyre Therapeutics, Inc.
Option exercise · 10b5-1 plan
M$2.15M
78.3K sh
May 1, 2026May 1, 2026
traded May 1, 2026
+0dSEC FORM 4

Evidence

27
SS
Sloan SheldonChief Medical Officer
SYRESpyre Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$1.48M
21.3K sh
May 1, 2026May 1, 2026
traded May 1, 2026
+0dSEC FORM 4

Evidence

27
SS
Sloan SheldonChief Medical Officer
SYRESpyre Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$1.39M
19.7K sh
May 1, 2026May 1, 2026
traded May 1, 2026
+0dSEC FORM 4

Evidence

24
SS
Sloan SheldonChief Medical Officer
SYRESpyre Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$628K
8,777 sh
May 1, 2026May 1, 2026
traded May 1, 2026
+0dSEC FORM 4

Evidence

24
SS
Sloan SheldonChief Medical Officer
SYRESpyre Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$932K
12.8K sh
May 1, 2026May 1, 2026
traded May 1, 2026
+0dSEC FORM 4

Evidence

28
SS
Sloan SheldonChief Medical Officer
SYRESpyre Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$764K
10.4K sh
May 1, 2026May 1, 2026
traded May 1, 2026
+0dSEC FORM 4

Evidence

22
SS
Sloan SheldonChief Medical Officer
SYRESpyre Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$30K
400 sh
May 1, 2026May 1, 2026
traded May 1, 2026
+0dSEC FORM 4

Evidence

9
SS
Sloan SheldonChief Medical Officer
SYRESpyre Therapeutics, Inc.
Grant or award
A—
140.0K sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC FORM 4

Evidence